| Title |
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
|
|---|---|
| Published in |
Targeted Oncology, October 2014
|
| DOI | 10.1007/s11523-014-0343-8 |
| Pubmed ID | |
| Authors |
Katerina Kubackova, Z. Bortlicek, T. Pavlik, B. Melichar, Z. Linke, P. Pokorna, R. Vyzula, J. Prausova, T. Buchler, on behalf of the Czech Renal Cancer Cooperative Group |
| Abstract |
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70 % were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15 % of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time ≤1 year from diagnosis to first-line systemic treatment, performance status ≥2, low hemoglobin, and LDH >1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor > Associate Professor | 2 | 25% |
| Unspecified | 1 | 13% |
| Student > Doctoral Student | 1 | 13% |
| Other | 1 | 13% |
| Researcher | 1 | 13% |
| Other | 1 | 13% |
| Unknown | 1 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 50% |
| Unspecified | 1 | 13% |
| Psychology | 1 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 13% |
| Unknown | 1 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2014.
All research outputs
#20,239,689
of 22,766,595 outputs
Outputs from Targeted Oncology
#508
of 549 outputs
Outputs of similar age
#213,973
of 256,317 outputs
Outputs of similar age from Targeted Oncology
#4
of 6 outputs
Altmetric has tracked 22,766,595 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 549 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,317 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.